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Abstract
Aims/hypothesis Classically, type 1 diabetes is thought to
proceed to absolute insulin deficiency. Recently developed
ultrasensitive assays capable of detecting C-peptide under
5 pmol/l now allow very low levels of C-peptide to be detected
in patients with long-standing type 1 diabetes. It is not known
whether this low-level endogenous insulin secretion responds
to physiological stimuli. We aimed to assess how commonly
low-level detectable C-peptide occurs in long-duration type 1
diabetes and whether it responds to a meal stimulus.
Methods We performed a mixed-meal tolerance test in 74
volunteers with long-duration (>5 years) type 1 diabetes, i.e.
with age at diagnosis 16 (9–23)years (median [interquartile
range]) and diabetes duration of 30 (19–41) years. We
assessed fasting and stimulated serum C-peptide levels using
an electrochemiluminescence assay (detection limit 3.3 pmol/l),
and also the urinary C-peptide:creatinine ratio (UCPCR).
Results Post-stimulation serum C-peptide was detectable at
very low levels (>3.3 pmol/l) in 54 of 74 (73%) patients. In all
patients with detectable serum C-peptide, C-peptide either
increased (n =43, 80%) or stayed the same (n =11) in response
to a meal, with no indication of levels falling (p <0.0001).
With increasing disease duration, absolute C-peptide levels
fell although the numbers with detectable C-peptide remained
high (68%, i.e. 25 of 37 patients with >30 years duration).
Similar results were obtained for UCPCR.
Conclusions/interpretation Most patients with long-duration
type 1 diabetes continue to secrete very low levels of endog-
enous insulin, which increase after meals. This is consistent
with the presence of a small number of still functional beta
cells and implies that beta cells are either escaping immune
attack or undergoing regeneration.
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Introduction
Type 1 diabetes is defined as a disease of progressive autoim-
mune destruction of beta cells, leading to absolute insulin
deficiency. The decline in insulin production in patients diag-
nosed with type 1 diabetes is variable. Most (92–97%) pa-
tients at more than 5 years from diagnosis have a stimulated
serum C-peptide value <200 pmol/l [1]. Enduring endogenous
insulin production has a protective effect on microvascular
complications and hypoglycaemia [2].
The prevalence of detectable C-peptide in type 1 diabetic
patients depends on several factors including duration of
diabetes, age at diagnosis, the type and timing of sample
collection (e.g. after a stimulus), and by the sensitivity of
assays used [3–5]. There have been recent improvements in
the sensitivity of C-peptide assays. Thus Wang et al reported
that, using an ultrasensitive ELISA, C-peptide can be detected
in fasting blood samples of 43% of patients with type 1
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diabetes after a median disease duration of 15 years [6]. In
keeping with this finding, insulin-containing beta cells have
long been identified in pancreatic autopsy specimens of type 1
diabetic patients and more recently have been demonstrated to
be present in up to 88% of patients with long-duration type 1
diabetes [7–10]. It is not clear whether the very low levels of
C-peptide detected and the beta cells visible in autopsy spec-
imens reflect functioning beta cells that can respond to a
physiological stimulus.
The urinary C-peptide:creatinine ratio (UCPCR) is a re-
cently described method of assessing C-peptide production
that involves using a spot urine test. It is a reliable, sensitive
and specific method for assessment of insulin secretion in type
1 diabetes, with test material remaining stable for 3 days at
room temperature, allowing outpatients to easily be tested
[11, 12]. No studies have assessed the ability of UCPCR to
detect low-level insulin production.
We aimed to assess the prevalence of detectable C-peptide
in patients with long-duration type 1 diabetes and determine
whether low-level C-peptide rises after a meal stimulus. This
was done using serum and urine samples to assess their
relative sensitivity.
Methods
Study participants We recruited 74 participants who had had
type 1 diabetes for longer than 5 years. Participants had either
been diagnosed at less than 30 years of age (n =68) or when
older than 30 years and with islet autoantibodies present
(n =6). All patients had been on insulin since diagnosis. Of
the 74 participants, 38 (51%) were male. Age at diagnosis
was 16 (9–23)years, median (interquartile range [IQR]),
and duration of diabetes was 30 (19–41)years, with BMI
of 25 (23–28)kg/m2, HbA1c 7.9 (7.2–9.0)% (63 [55–75]
mmol/mol), insulin dose 0.55 (0.44–0.69)units per kg of body
weight per day and an estimated GFR of 89 (82–102)mlmin−1
1.73 m−2.
Informed consent was obtained from all participants and
the study was approved by the National Research Ethics
Service Committee South West (09/H0206/25).
Mixed-meal tolerance test Participants attended the Exeter
National Institute for Health Research (NIHR) Clinical Re-
search Facility for a standard mixed-meal tolerance test [3, 12,
13], having fasted from midnight, not taken their usual morn-
ing insulin and fully emptied their bladder upon waking.
Fasting blood was taken for measurement of C-peptide, cre-
atinine, glucose, HbA1c, and GAD and islet antigen 2 autoan-
tibodies, and a second void urine sample [11] was collected
for UCPCR determination. Participants were given a standard
mixed meal (Ensure Plus HP; Abbott Nutrition, Columbus,
OH, USA) consisting of 6 ml/kg (maximum 360 ml) water
and containing per 100 ml: 15.9 g carbohydrate, 7.9 g protein,
3.3 g fat and 125 kJ energy. Blood was taken for C-peptide
and glucose analysis at 90 min post-completion of the mixed
meal, with urine being collected for UCPCR determination at
120 min. All participants were asked to provide a home urine
sample in a boric acid container [11, 12], taken 2 h after an
eveningmeal (and having voided the bladder before the meal).
Serum and urine samples were stored at −80°C for subsequent
analysis.
C-peptide analysis We analysed serum C-peptide with a di-
rect electrochemiluminescence immunoassay using mouse
monoclonal anti-C-peptide antibody (Roche Diagnostics,
Mannheim, Germany) on an E170 analyser (Roche). The
reported limit of detection is 3.3 pmol/l with a CV of 0.6%
at 33 pmol/l.
We compared our Roche assay with another assay,
Ultrasensitive C-peptide ELISA (Mercodia, Sylveniusgatanm,
Sweden), which is a solid-phase two-site enzyme immunoassay
that uses a peroxidase-TMB (3,3′,5,5′-tetramethybenzidine)
label on an automated ELISA system (Dynex DSX; Launch
Diagnostics, Longfield, UK). The comparison involved dual
analysis of 67 samples selected for having low levels of serum
C-peptide. The reported limit of detection is 1.5 pmol/l with a
CVof 5.5% at 37 pmol/l.
Urinary C-peptide was analysed on the E170 analyser
(Roche) as previously described [11].
Data analysis As C-peptide results were not normally distrib-
uted, we used non-parametric statistical tests. A Wilcoxon’s
signed rank test was used to compare fasted and stimulated
C-peptide levels. McNemar’s test was used to compare pro-
portions detectable by different limits. Bland–Altman plots
were used to assess the comparability of results from the Roche
and Mercodia assays. Statistical analysis was performed using
IBM SPSS version 20 (IBM, Armonk, NY, USA).
Results
C-peptide is detectable in most people with long-duration type
1 diabetes Serum C-peptide was detectable (>3.3 pmol/l ) in
54 of 74 (73%) patients with type 1 diabetes of more than
5 years duration when measured at 90 min post meal; in
the fasted state it was detectable in 49 of 74 (66%)
participants.
The detection limit makes a considerable difference to the
number of patients in whom C-peptide was detected (Fig. 1).
Only 35% (26 of 74, p <0.0001 compared with 3.3 pmol/l) of
patients had detectable stimulated C-peptide at a cut-off of
30 pmol/l, which is a previously published limit of detection
[8], with 20% (15 of 74) of patients having a C-peptide
value above a cut-off of 200 pmol/l, which is commonly used
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as a definition of significant endogenous insulin secretion
[14].
The impact of using a modern assay with a lower limit of
detection is more apparent with increasing disease duration.
Thus in participants with diabetes of over 30 years duration,
C-peptide was >3.3 pmol/l in 25 of 37 (68%) and >30 pmol/l
in four of 37 (11%, p <0.0001) participants.
Low-level C-peptide is functionally responsive C-peptide rose
from a median (IQR) fasting value of 12 (10–80)pmol/l to 23
(12–257)pmol/l after a mixed meal (p <0.0001). In all 54
patients with detectable stimulated serum C-peptide
(>3.3 pmol/l), C-peptide either rose (n =43, 80%) or stayed
the same (n =11), with none having falling levels (p <0.0001)
(Fig. 2). Even in 36 patients with fasting serum C-peptide
<30 pmol/l, 69% (n =25) had a C-peptide rise after the mixed
meal.
Low-level insulin secretion can be detected using urinary
C-peptide Low-level insulin secretion can be detected by
measuring urinary C-peptide in patients with long-duration
type 1 diabetes. Most patients, i.e. 51 of 74 (69%), had
detectable C-peptide (>30 pmol/l) in urine taken at 120 min
after the mixed meal. There was high concordance between
participants who had C-peptide detected by both methods,
with 50 of 51 participants with detectable urinary C-peptide
also having detectable serum C-peptide. In the 51 patients
with detectable urinary C-peptide, the UCPCR rose in 46
(90%) and fell in five (p <0.0001) after a mixed meal. Sam-
ples taken at home 2 h after an evening meal and while on
insulin therapy showed similar results (Table 1).
C-peptide measurement and duration of diabetes Absolute
C-peptide levels fell as duration of diabetes increased
(Spearman’s correlation −0.46, p <0.0001) (Fig. 1). However,
the 20 patients with undetectable stimulated serum C-peptide
had a similar disease duration to those with detectable
C-peptide, i.e. 27 (18–42) vs 35 (26–40)years (median
[IQR], p =0.3).
Comparison of serum C-peptide assay methods The Roche
assay was able to measure C-peptide in samples in which it
was not measurable by the Mercodia assay, although the
former apparently has a higher limit of detection (3.3 vs
1.5 pmol/l) (see electronic supplementary material [ESM]
Results). The Mercodia assay consistently gave a lower C-
peptide value for the same samples than did the Roche assay
(14 vs 36 pmol/l, p <0.0001, by the Bland–Altman plot) (ESM
Fig. 1), showing a proportional bias with the largest difference
at higher levels of C-peptide.
Fig. 1 Scatterplot of serumC-peptide at 90min after a mixed meal (log10
scale) against duration of diabetes. Dotted reference lines indicate 200, 30
and 3.3 pmol/l. MMTT, mixed-meal tolerance test
Fig. 2 The effect of a meal stimulus on serum C-peptide levels in
participants with detectable insulin (n =54). (a) Paired fasting and mixed
meal results for all patients with detectable C-peptide. Each line repre-
sents an individual patient. (b) Results for all patients with fasting
C-peptide below 30 pmol/l (n =36). Of 54 patients, 34 (80%) had a serum
C-peptide value that rose after the mixed meal. None had a fall in the
C-peptide value after the meal








74 11 (0–30) 73 (54/74)
Serum C-peptide at 90 min
after MMTT (pmol/l)
74 12 (0–63) 66 (49/74)
Fasting UCPCR from
2nd voiding (nmol/mmol)
72 0.01 (0–0.08) 68 (49/72)
UCPCR at 120 min after
MMTT (nmol/mmol)
74 0.03 (0–0.18) 68 (50/74)
UCPCR after home
meal (nmol/mmol)
72 0.01 (0–0.09) 68 (49/72)
MMTT, mixed-meal tolerance test
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Discussion
We found persistent C-peptide secretion, which increased after
a meal stimulus, in the majority of patients with type 1 diabetes
and a disease duration of more than 5 years. We propose that
patients with a detectable stimulated C-peptide value
of <30 pmol/l, which would not have been detected with older
assay technologies, should be called insulin microsecretors.
Our finding that 73% of patients with type 1 diabetes of
more than 5 years duration (median 29 years) had detectable
C-peptide is consistent with previous studies. In a recent
study, Wang et al demonstrated that 43% of patients with type
1 diabetes had detectable fasting C-peptide after a median
disease duration of 15 years [6]. In Joslin medallists (diabetes
duration >50 years), 67% had a detectable random C-peptide
(>30 pmol/l). Indeed, it was suggested that this enduring
C-peptide may have contributed to the patients’ survival [8].
An important finding is the response of very low-level
C-peptide to a mixed meal. This strongly supports the notion
that the residual beta cells are functional and excludes the
possibility that very low levels of C-peptide are the result of
analytical noise. Other studies have not directly addressed the
responsiveness of these patients with very lowC-peptide levels.
In Joslin medallists, the response to a mixed meal was only
studied in those with C-peptide over 100 pmol/l [8], but we
report here that a response occurred in the majority of patients
with a C-peptide concentration <30 pmol/l. Wang et al reported
a correlation between glucose levels and low-level C-peptide in
three patients with serial random C-peptide measurements over
3 months, but did not look at the direct response to a meal [6].
Our results provide clear evidence that the infrequent beta
cells seen in histological studies of long-duration type 1 dia-
betes are still functional. Occasional beta cells have been
noted in histological studies of patients with long-standing
type 1 diabetes since 1965 [9, 10]. These were shown recently
to be present in the pancreases of most patients [7, 8]. The
received wisdom was that these beta cells were not functional,
as older assays could not detect C-peptide in long-standing
cases of type 1 diabetes. Our finding that low-level C-peptide
in people with type 1 diabetes increases after a meal estab-
lishes that these rare isolated islets are functional.
We detected low-level C-peptide production not only in
analyses of serum, but also of urine. This is an important point
for future studies. The stability and non-invasiveness of single
sample UCPCR means tests can be done at home. This could
facilitate large community/cohort studies and provide a way to
easily identify insulin microsecretors for future investigation.
Our study has limitations. The patients studied were not
randomly selected from a population-based sample of patients
with type 1 diabetes as would be the case for a true epidemi-
ological cohort. We cannot rule out the possibility that some
patients with non-type 1 diabetes were inadvertently included,
although this is unlikely to be a major source of error, as a tight
definition of type 1 diabetes was used and the absolute levels of
C-peptide found were far lower than those described in type 2
diabetes orMODY [15]. The lack of assay standardisationmakes
it difficult to compare the prevalence of persistent C-peptide
production when assessed by different assays [16, 17]; our
comparison of the methods showed that the Roche assay detects
low-level C-peptide in more patients than the Mercodia assay.
Further work is needed to establish the clinical significance
and cause of insulin microsecretion. The benefits of residual
insulin microsecretion in terms of hypoglycaemia, microvascular
complications and long-term survival are unknown, but any im-
pact is likely to be small so that further studies will need to have
larger numbers of participants. The immunological and genetic
characterisation of patients with and without residual C-peptide
may help to explain why some people with type 1 diabetes have
enduring endogenous insulin secretion and some do not.
In conclusion, we were able to detect enduring low-level
insulin production in the majority of patients with type 1 diabe-
tes, even in those with very long disease duration. The increase
in C-peptide levels after a meal provides convincing evidence of
functionally responsive beta cells. This implies that beta cells are
either escaping immune attack or undergoing regeneration.
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